| References |
1. Katsanis E, Sapp LN, Pelayo-Katsanis L, Whitney K, Zeng Y, Kopp LM. Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies. J Pediatr Hematol Oncol. 2016 Nov;38(8):e315-e318. PubMed PMID: 27467368. 2. Boelens JJ, Rocha V, Aldenhoven M, Wynn R, O'Meara A, Michel G, Ionescu I, Parikh S, Prasad VK, Szabolcs P, Escolar M, Gluckman E, Cavazzana-Calvo M, Kurtzberg J; EUROCORD, Inborn error Working Party of EBMT and Duke University. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant. 2009 May;15(5):618-25. doi: 10.1016/j.bbmt.2009.01.020. PubMed PMID: 19361754. 3. Goebel WS, Nelson RP Jr, Brahmi Z, Gowan DJ, Towell PJ, Robertson KA, Haut PR. Serial transplantation resulting in tolerance to an unrelated cord blood graft. Transplantation. 2006 Jun 15;81(11):1596-9. PubMed PMID: 16770250. 4. Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S, Barnard DR, Wallace JD, Kalousek D, Lange BJ, Woods WG. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood. 2004 May 15;103(10):3655-61. Epub 2004 Jan 29. PubMed PMID: 14751924. |
